论文部分内容阅读
根据中华医学会核医学分会第七届委员会工作计划安排,核医学会临床治疗学组将牵头组织全国核医学同仁开展~(131)Ⅰ治疗 Graves 病多中心临床研究。目前,该项目已进入研究前期的准备工作,为了让更多符合条件的单位共同参与这项课题,现公开邀请愿意加盟的核医学有关单位。参加单位入选基本条件:①核医学科(单位)已取得相关部门颁发的证件(放射性药品许可证、放射工作卫生许可证等);②单位已开展~(131)Ⅰ治疗甲状腺功能亢进症(简称甲亢)3年以上,并建立了健全的核素治疗相关规章制度,有一定的工作经验;③接受~(131)Ⅰ治疗 Graves 病例数较多(原则上平均每年服~(131)Ⅰ治疗300人次以上);④具备甲状腺功能测定、有关免疫指标测定及甲状腺显像条件,最好能开展染色体检查;⑤能严格按照《临床技术操作规范》操作,记录详细,资料保管规范;⑥要求持续参与不少于10年,科室有很好的稳定性,有合理的人员梯队。欢迎各单位积极报名参加。请
According to the schedule of the work plan of the Seventh Committee of the Nuclear Medicine Branch of the Chinese Medical Association, the Clinical Therapeutics Section of the Nuclear Medicine Society will take the lead in organizing the multi-center clinical study of 131I treatment of Graves disease in national nuclear medicine colleagues. At present, the project has entered the preparatory work for the pre-research phase. In order to allow more qualified units to participate in the project, the nuclear medicine related units that are willing to join are openly invited. Participants selected for the basic conditions: ① nuclear medicine (unit) has been issued by the relevant departments issued a certificate (radiopharmaceuticals, radiological health permits, etc.); ② units have been carried out ~ (131) Ⅰ treatment of hyperthyroidism Hyperthyroidism) for more than 3 years, and established a sound nuclear medicine rules and regulations, have some work experience; ③ accept ~ (131) Ⅰ Graves treatment of patients with more cases (in principle, the average annual service ~ (131) Ⅰ treatment of 300 More than the number of people); ④ have thyroid function test, the determination of the immune index and thyroid imaging conditions, the best to carry out chromosome tests; ⑤ in strict accordance with the “clinical technical specifications” operation, record details, data storage norms; Not less than 10 years, departments have good stability, a reasonable staff echelon. All units are welcome to sign up actively. please